

Helsinki, 14 June 2024



2024



GENERAL ASSEMBLY

Organisation of European Cancer Institutes - EEIG



15

Cancer Centres/Institutes
have applied to the
OECI Full Membership





HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (Full Member)

Madrid – SPAIN

Dr. Enrique González Billalabeitia (Medical Oncologist)

Dr. María Calbacho Robles (Clinical Haematologist)





Hospital Universitario
12 de Octubre



12 de Octubre

University Hospital

Madrid (Spain)

14 June 2024



12 de Octubre Hospital (H12O)	
Location	Madrid
Opened	1973
Funding	Public hospital
Type	Teaching
Regional authorities	Regional Health Care Service: Servicio Madrileño de Salud (SERMAS)
Affiliated university	Universidad Complutense, Madrid.
Reference Hospital	Rare diseases and participation in Clinical trials
Employees	6,500
Emergency department	Yes
Patient beds	1,256
Helipad	2
Activity	1.3 million patients visits / year
Website	https://www.comunidad.madrid/hospital/12octubre/




TOP 100



UNIVERSIDAD COMPLUTENSE
MADRID


The reference in the south of Madrid





12 de Octubre Comprehensive Cancer Centre

Institutions:



2023 in Numbers



Cancer Care, Research,
Education and Training

ACTIVITY

**Newly diagnosed Cancer
Patients: 3812 patients**

**Hematopoietic stem cell
Transplantation : 109 patients**

**CART cells
22 patients**

PUBLICATIONS

308 PUBLICATIONS
68% Q1; 32% D1
CUMULATIVE IMPACT FACTOR: 4191

**PhD Thesis
11***

RESEARCH

**LABORATORY RESEARCH
119 Grants***



CLINICAL RESEARCH
On going clinical trials: 422
Early Drug Clinical Trials: 114
906 patients included

ACCREDITATIONS



HOSPITAL CLINIC DE BARCELONA

Barcelona – SPAIN

Dr. Aleix Prat - Director of the Cancer Institute





Clínic Comprehensive Cancer Center (4C) Barcelona, Spain

OEI General Assembly – 14th June 2024

Dr. Aleix Prat, MD PhD

Director Cancer Institute and Blood Disorders

Professor, University of Barcelona

Researcher at FCRB-IDIBAPS

Campus Clínic since 1906



Assistance – Teaching – Clinical Research – Innovation – Translational Research



4 venues

850 beds

49,000 hospital admissions

785,000 outpatient visits


160,000 emergency visits

26,000 surgical interventions

7,500 health professionals

800 M € budget

4C Governance



Clinic Cancer Institute – A key component of the 4C



- **Medical Oncology**
- **Hematology and Hemotherapy**
- **Radiation Oncology**

510 professionals, 70 hospital beds, 3 Day Hospitals, 1 Clinical Trials Unit, 4 Radiotherapy accelerators, 5 Research Groups, 4 Chairs at the University of Barcelona

4C Clinical and Translational Research Output



>400 clinical trials ongoing

510 patients recruited annually
(17% of all new patients)



30 research groups

534 original articles
in cancer in 2022

3 spin-off companies

Three key milestones of the 4C



ARI-0001 (CAR-T CD19)

ARI-0002 (CAR-T BCMA)

Why we want to be part of the OECl

- Integration into a Prestigious Network
- Enhancement of Research and Clinical Standards
- Collaborative Opportunities
- Visibility and Recognition
- Patient-Centric Focus
- Support and Advocacy

Benefits for OECl

- Strengthened Network
- Research Contributions
- Educational Synergy
- Innovative Approaches
- Geographical Expansion
- Collaborative Projects



Thank you



**Clínic
Barcelona**



**UNIVERSITAT DE
BARCELONA**

FINNISH CANCER CENTER – FICAN (Full Member)

Helsinki – FINLAND

Professor Tomi P Mäkelä


Director, Finnish National Cancer Center FICAN



Finnish Cancer Center

Professor, Director Tomi Mäkelä


OECl Oncology Days, General Assembly 14.6.2023



FICAN

Finnish Cancer Center FICAN

- Mission to enable tomorrow's cancer care in Finland
- Established 2018-19
- A network of five regional centers with a coordinating unit
- Stakeholders include regional health care providers (18) and medical universities (5)





Finnish Cancer Center FICAN

- Mandated by legal decree to
 - Plan and align national activities in **prevention, diagnostics, treatment, and rehabilitation**
 - Ensure strong research base
- Coordinates and aligns regional and national activities




OECI CCCs and CCs as core of FICAN

- FICAN South: HUS Comprehensive Cancer Center
- FICAN West: TYKS Cancer Center
- FICAN Mid: TAYS Cancer Center
- FICAN East: KYS Cancer Center
- FICAN North: OYS Cancer Center - in A&D process




Added value

- National planning and guidance of screening programs
- Coordinating guidelines (e.g. CRC, Prostate cancer)
- Implementing European Beating Cancer Plan and Mission Cancer
 - ERN-EURACAN, PRIME-ROSE, PCM4EU, EOSC4 Cancer, ECHoS, UNCAN.eu
- Facilitating national precision cancer medicine research & research training projects
 - CancerIO, Finnprove, iCAN
 - iCANDOC Precision Cancer Medicine doctoral training pilot (38 M€ 2024-27)




Looking ahead

- Finnish Cancer Strategy by May 2025
- National Cancer Mission Hub Finland as part of European network
- Finnish Health RDI Program – FICAN one of national competence centers
- Quality registry for cancer
- Precision Cancer Medicine Program
- Contributing to OECl network development



Motivation to apply OECl membership

- Goals of OECl and FICAN align
- 4/5 regional university hospitals accredited as CC or CCC OECl centers
- Does not make sense to start a separate evaluation/accreditation process
- Attempt to broaden good practices beyond current OECl accredited centers
- Contribute to OECl network development



Thank you!



CENTRE ANTOINE LACASSAGNE

(Full Member)

Nice – FRANCE

Prof. Emmanuel Barranger

General Manager



Application 2024



Antoine Lacassagne Cancer Center NICE (Fédération UNICANCER)


Pr Emmanuel BARRANGER
Général manager



A member of the 18 french Cancer Centers (CLCC) of the UNICANCER network

« Our commun signature »

- Prevention, care, research and teaching
- **Comprehensive care (medical, psychological and social), from screening to supportive care**
- 20% patients with cancer treated in CLCC (<1% national bed capacity)
- **15% patients included in clinical trial**



CAL

200 beds

Healthcare

6,400 new patients

32,000 radiotherapy sessions

20,000 chemotherapy sessions
séances de CT

4000 surgical procedures séjours

Teaching

30 residents 60 students

7 university professors

Research

173 open clinical trials

411 patients enrolled **10%**

77 early phase trials

Protontherapy technology



Ocular tumor treatment



Complete radiotherapy technical platform

CAL ide ntit y

National recognition for early clinical research

First health group in France with the teaching hospital
« Head and Neck Institute »



Institut Universitaire de la Face et du Cou



National and international recognitions for care quality

First national comprehensive supportive care center (collaboration with territorial collectivity)



Why OEIC labelisation ?



- High level of quality
- European network, harmonisation of care for cancer

For the CAL

- Will reinforce the CAL internal structuration
- Will valorize positioning and attractivity
- Will stimulate research and progress in treatment

THANK YOU FOR YOUR ATTENTION



Antoine Lacassagne
CENTRE DE LUTTE CONTRE LE CANCER
unicancer NICE

**60 ANS DE LUTTE
CONTRE LE CANCER**

L'Humain avant tout • L'Expertise • L'Engagement • L'Innovation

LANDSPÍTALI UNIVERSITY HOSPITAL

(Full Member)

Reykjavik – ICELAND

Dr Vigdís Hallgrímsdóttir



**LANDSPÍTALI UNIVERSITY
HOSPITAL**

OECI General Assembly

Vigdís Hallgrímsdóttir

Executive Director of Cardiovascular-,
Ophthalmology- and Cancer services



The Icelandic National Health Service

- Health care centers throughout the country deliver primary care
- Landspítali University Hospital provides general services for the Reykjavik area and tertiary care for the entire nation
- Akureyri Hospital, a teaching hospital in the Northern part of the country, delivers specialized care for the region
- Six small district general hospitals
- Private medical practice
- Generally good access to health services
- Universal health insurance



The Icelandic population: 384,000 in 2024

248,000 reside in the Capital Region

Landspítali

The only university hospital and largest organization in Iceland

€ Budget 625 million
Eur

6.400 employees



2.000 students

40 medical
specialties



91.500 emergency
visits

331.000 outpatient
visits



26.400 admissions

650 hospital beds



4,8 days average
length of stay

13.200 surgical
procedures



3.109 births



Low cancer incidence and mortality

Iceland vs. OECD





Figure 3.14. Cancer mortality rates by sex, 2021 (or nearest year)




Source: IARC GLOBOCAN 2020, OECD Health Statistics 2021.

Cancer risk factors Iceland vs. OECD


Figure 4.1. Population aged 15 and over smoking daily, by sex, 2021 (or nearest year)




Figure 4.12. Self-reported overweight and obesity rates among adults, by sex, 2021 (or nearest year)




Cancer registry in Iceland for 70 years




Prediction of number of new cancer cases in Iceland in 2040



Prediction of number of cancer survivors in Iceland 2040




Prediction of proportional increase in new cancer cases in the Nordic countries in 2040 (Nordcan)



Cancer service at Landspítali



Cardiac-, ophthalmology- and cancer services Executive Director



250 FTE's

27.300 outpatient visits



1.400 inpatient admissions

44 inpatient beds



13.000 radiation therapy visits

MDT for all major cancer types



20.000 palliative home care visits

17.300 chemotherapy visits









Closed loop medication system for chemotherapy improves patient safety



Landspítalinn í Fossvogi. Lýðmyndir.is

Nýtt fyrirmælakerfi fyrir krabbameinslyf sem tekið hefur verið í notkun á Landspítalanum mun auka öryggi lyfjagjafa er kemur fram á vef Landspítalans.

Þar segir að fyrirmælakerfið sé viðbót við CATO-lyfjablöndunarkerfið sem hefur á undanförmum árum verið notað í lyfjablöndun á Landspítala.

„Með fyrirmælahlutanum er allt sem við kemur krabbameinslyfjum í einu og sama kerfinu. Þannig hefur orðið til fyrsta lokaða lyfjakerfið á spítalanum,“ segir á vefnum.

 Landspítali
13. desember 2022 · 🌐

Nú er verið að leggja lokahönd á innleiðingu á nýju lyfjakerfi í krabbameinsþjónustunni. Kerfið er stafrænt og byggir á strikamerkjum og skönnum sem tryggja að sjúklingar fái örugglega rétt lyf á réttum tíma. Það skiptir sérstaklega miklu máli í meðferð krabbameins.

Þverfaglegt teymi lækna, hjúkrunarfræðinga, lyfjafræðinga og tölvunarfræðinga hefur unnið að innleiðingunni í rúm t ár.



👤 Fjalar Jóhannsson, Adeline Tracz og 317 til viðbótar 18 ummæli 25 deilingar

👍 Líkar þetta 💬 Skrifa ummæli ➦ Deila



New hospital building



HOSPITAL UNIVERSITARIO LA PAZ (Full Member)

Madrid – SPAIN

Javier De Castro Carpeño





LA PAZ UNIVERSITY HOSPITAL

Madrid, SPAIN



Helsinki, 14th June, 2024



COMMITTED IN COMPREHENSIVE HEALTH CARE

HEALTH CARE

EXCELLENCE

EDUCATION

RESEARCH
& INNOVATION

RESEARCH AND
INNOVATION INSTITUTE


SCHOOL OF MEDICINE
CAMPUS

GENERAL HOSPITAL

CHILDREN
HOSPITAL

TRAUMA CENTER

WOMEN'S HOSPITAL



- 7.500 WORKERS
- 1.200 MEDICAL DOCTORS
- 600 TRAINING DOCTORS
- 17 BUILDINGS
- ALL MEDICAL SPECIALITIES
- 200 MEDICINE STUDENTS

- 1.204 BEDS
- 48.637 HOSPITAL ADMISSIONS
- 34.479 SURGERIES
- 272.210 FIRST MEDICAL CONSULTATIONS
- 906.645 SUCCESSIVE MEDICAL CONSULTATIONS
- 1.178.855 TOTAL CONSULTATIONS
- 251.318 MEDICAL EMERGENCIES

- POPULATION AREA: 600.000 INHABITANTS
- MADRID: NORTH REGION

INTEGRATIVE CANCER CARE

EDUCATION

RESEARCH & INNOVATION

PRIMARY CARE

HOSPITAL

- POPULATION HEALTH EDUCATION
- PRIMARY PREVENTION
- SCREENING
- EARLY DETECTION
- PATIENT MONITORING
- HOME TREATMENT
- PALLIATIVE CARE
- LONG SURVIVORS

- HIGH RESOLUTION DIAGNOSIS
- MULTIDISCIPLINARY TEAMS
- MULTIDISCIPLINARY BOARDS FOR DECISION MAKING
- FUNCTIONAL UNITS
- MOLECULAR TUMOR BOARDS
- CLINICAL TRIALS AND INNOVATIVE THERAPIES
- SIDE EFFECTS MONOGRAPHIC UNITS
- PALLIATIVE CARE UNIT
- LONG SURVIVORS

PEOPLE/PATIENTS ALONG THE PROCESS

CANCER GOVERNANCE STRATEGY

Medical Oncology

22 Medical Oncologist

New patients/year: 1719

Consultants: 40.102

Oncological treatments: 28.814

Follow-up: 7352 Virtual calls: 3912

Hereditary cancer: 949 new patients /1.348 follow-up

Nursing office: 14.206

Clinical trials nursing: 3.303

Long survivors follow-up: 1347

24 beds inpatient area



Onco-haematology

11 Onco-hematologist

2 haematologist (Celular Therapy/Trasplant)

2 haematologist Blood Bank

New patients/year: 4171

Follow-up: 14843

18 beds, 4 positive pressure isolation

Transplants/year: Allogenics 16 /Autologous 25

Onco-hematology Pediatrics

15 Onco-haematologist

New patients/year: 125


Follow-up: 8935

24 beds, 5 positive pressure isolation

Allogenics transplants/year: 38

Cellular therapy: 40 patients treated with advanced therapies

Radiotherapy




- 14 radiotherapist
- 24 radiotherapy technicians
- NORMA ISO 9001:2015 / UNE 179003

Surgical Oncology

- 6 Breast surgeons → 400 breast cancers
- 22 G-I surgeons. → 500 colorectal cancers
- 7 Gynecological surgeons → 250 Gyn cancers
- 6 H & N surgeons → 250 H&N cancers
- 7 Thoracic surgeons → 120 lung cancers
- 518 pediatrics surgeries

- Robotic surgery
- 3-D Lab



- Next Generation Sequencing

Pathology


- 18 pathologist

68.000 biopsies
41.000 citologies

- Biobank




Cancer Registry (10 years)





The cancer patient experience





PHASE I/II CLINICAL TRIAL UNIT

- A hospital ward with eight beds and four chairs (children and adults)

First-in-human (FIH) studies

FIH in advance therapies (oncology)

Pharmacokinetics/Pharmacodynamics (PK/PD)

Bioequivalence (BE) Single/Multiple Dose

Bioavailability (BA)

Food Effect/Drug-food Interaction

Drug-Drug Interactions (DDI)



ADVANCED THERAPIES UNIT

Cell therapy processing unit: apheresis, cell processing, freezing and storage. Positive selection of CD45 lymphocytes for infant transplantation. Selection of immunocompetent lymphocytes for CMV and BK infections.

- **Clinical trials/5 years: 1164**
- **Principal Investigators: 70**
- **Patient enrolled/year: 500**
- **Clinical trials in children: 34**
- **Children enrolled/year: 160**

CLINICAL RESEARCH


Basic and Traslational Research




Cell Cultures



Sequencing



Advanced Imaging



Cancer and Human Molecular Genetics Area

Area Coordinators: Javier de Castro Carpeño
Inmaculada Ibáñez de Cáceres

INGEMM- Institute of Medical and Molecular Genetics Group
Director: Pablo Lapunzina Badia

Translational Oncology Group
Director: Jaime Feliú Battle

Experimental Therapies and Biomarkers in Cancer Group
Directors: Inmaculada Ibáñez de Cáceres
Javier de Castro Carpeño

Oto-Neurosurgery Research Group
Director: Luis Lassaletta Atienza

Cancer Molecular Pathology and Therapeutic Targets Group
Director: David Hardisson Hernández

Mechanisms of Tumour Progression Group
Director: José Manuel González Sancho

Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells Group
Director: Carmela Calés Bourquet

Research and Diagnosis of Inherited Metabolic Diseases Group
Director: María Belén Pérez González

Dyslipemias of Genetic Origin and Metabolic Diseases Group
Director: Sonia Rodríguez Novoa

Human Genetic Variability Group
Director: Ana Fernández Santander

Programme	Organisation	Total
Ramón y Cajal Stabilisation Contracts (13)	CM	3
Miguel Servet Stabilisation Contracts (12)	ISCIII/CM	15
Technical Support Stabilisation Contracts	CM	2
TOTAL ESTABLISHED		20
Miguel Servet Contracts CP Type 1	ISCIII	4
Miguel Servet Contracts CP Type 11	ISCIII	1
Intensification Contracts	ISCIII	5
Río Hortega Contracts	ISCIII	9
Juan Rodés Contracts	ISCIII	4
Bioinformatics Technical Contract	ISCIII	1
Sara Borrell Contract	ISCIII	5
Seal of Excellence ISCIII-HEALTH	ISCIII	1
Predoctoral Fellowship	ISCIII	9
Investigo Programme Contracts	SEPE	15
Predoctoral Contract	MINECO	2
Youth Guarantee Contracts	CM	6
TOTAL PROGRAMMES		62
TOTAL ESTABLISHED + PROGRAMMES		82
UCICEC	CAIBER	11
FIS Projects	ISCIII	15
European Projects	EU	21
Research Network	ISCIII	8
Research Network	CM	1
SAF/MAT	MINECO	3
Biobank	ISCIII	5
Commercial clinical trials	ISCIII	5
Commercial clinical trials	EECC Promoters	44
Private projects	Pharmaceutical Industry	87
In-house Projects	FIBHULP	8
ITEMAS Network	ISCIII	3
TOTAL EMPLOYEES DEPENDENT ON P.I.		211
TOTAL STAFF DEPENDENT ON P.I.		293
Technical Unit Staff	FIBHULP	19
TOTAL TECHNICAL UNIT		19
TOTAL		312

	Total	%Q1	%D1
Publications	1,620	39.94	13.27
Owned Publications	684	30.85	7.02
Un-owned Publications	936	46.58	17.84
Originals	1,295	39.31	12.90
Owned Originals	501	29.94	5.79
Un-owned Originals	794	45.21	17.38
JCR Indexed* Articles and Reviews	1,434	40.44	13.04
Owned JCR Indexed* Articles and Reviews	566	30.91	6.36
Un-owned JCR Indexed* Articles and Reviews	868	46.65	17.39

**University Hospital Erlangen - BZKF Office
(Full Member)**

Erlangen – GERMANY

Professor Dr. Wolfgang Weber

Member of the Board of Directors of the BZKF



Bavarian Cancer Research Center (BZKF)

Bavaria

Chat-GPT 4.o 6/24



Bavarian Cancer Research Center (BZKF)

Big enough to make an impact, small enough to remain nimble.



Coalition of all 6 universities and their affiliated university hospitals in Bavaria:

- Augsburg
- Erlangen
- Munich (LMU)
- Munich (TUM)
- Regensburg
- Würzburg

Founded in 2018


13.4 Million inhabitants. 716 Billion Euro GDP
Founded 554 (Germany 1872)



Main aim of the BZKF




Significantly **improve** the **care** of cancer patients in Bavaria
regardless of their residence (urban or rural)




How?

Strengthen excellence – share knowledge




Achieved by various BZKF structures



- Structural and project based funding allows efficient transfer and exchange of expertise and knowledge
- Cooperation with local or international industrial partners

Achieved by various BZKF structures



Selected key achievements to date



- Clinical trial support
 - Patients access to early clinical trials (Interdisciplinary Early Clinical Trial Unit)
 - Central point of contact for inquiries from the pharmaceutical & medical engineering industry
 - Clinical trial registry
 - Clinical trial contract for joint, cross-site clinical studies and trials
 - IMPD office for support of investigator initiated clinical trials
 - Implementation of quality standards for collecting and storing bio samples

• Selected key achievements to date



- Infrastructure for clinical research care of cancer patients
 - Facility for GMP facility for cellular immunotherapies
 - Decentralized OMICs core facility
 - Harmonization of IT structures (clinical and imaging data)
 - Establishment of an AI and Bioinformatics Competence Center (KIBCU)
 - Establishment of a radiopharmaceuticals network across Bavaria
 - Public Cancer Hotline (free, providing access to clinical trials, support groups, information)
 - Foundation of Patient Expert Pool

Bavarian Cancer Research Center (BZKF)



Thank you



HOSPITAL UNIVERSITARIO RAMON Y CAJAL

(Full Member)

Madrid – SPAIN

Dr Mingo, Director Manager



Raising the Standard in the Fight Against Cancer

Ramón y Cajal University Hospital accreditation candidacy by OECI



Introduction: Our Purpose and Focus on Cancer



Purpose

- **Improving People's Health and Well-being by Transforming Healthcare.**



Cancer Care

- **Excellence at Every Step of the Way.**
- **Transforming Health, Improving Lives.**
- **We Care for Your Well-being, We Innovate Your Health**




**Comunidad
de Madrid**

Ramón y Cajal University Hospital, Madrid, Spain

Madrid Region
population:
6.863.539

Population assigned RyC:
606.454 citizens (8,,83%)

Population Madrid Hospitals



Hospital Universitario
Ramón y Cajal



- **780** in patients' beds
- **45** operating rooms
- **20** associated clinics, **2** specialized, **4** mental health
- **1** outpatient care facilities with **31** chairs and bed
- **13** Reference Units for the National Health System (4 cancer related)
- **5874** workers: 1019 faculties and 1471 nurses



HEALTHCARE
SERVICES



EDUCATION




RESEARCH




Comunidad
de Madrid

Ramon y Cajal University Hospital : Healthcare Services



Ramon y Cajal University Hospital: Education



Universidad de Alcalá



Hospital Universitario Ramón y Cajal



Comunidad de Madrid

Ramon et Cajal Health Research Institute (IRYCIS): Indicators



Every man can become, if he wants to, the sculptor of his own brain.

Santiago Ramon y cajal

IRYCIS - RESEARCH INNOVATION SERVICES - CALLS TRAINING COMMUNICATION

118	1187	1284	126	1243
INNOVATION PROJECTS	PEOPLE	ANNUAL PUBLICATIONS	RESEARCH COMPETITIVE PROJECTS	CLINICAL TRIALS

AREA 1
Neurosciences, sense organs and mental health

AREA 2
Microbiology, Immunology and Infection

AREA 3
Cancer

AREA 4
Tools for Advanced Medicine

AREA 5
Chronic Pathologies and Surgery Research

AREA 6
Epidemiology, Public Health and healthcare



Comunidad de Madrid

IRYCIS Groups Working in Cancer Research: 14



Universidad
de Alcalá



SaludMadrid
Hospital Universitario
Ramón y Cajal

INSTITUTO
RAMÓN Y CAJAL DE
INVESTIGACIÓN SANITARIA



Comunidad
de Madrid

IRYCIS: Leadership in European and Global Health

BIOMARKER S PLT EU Platform-Chair (IRYCIS, ES)

eatris SPAIN

Privacy & Cookies Policy

EUGLOH
European University Alliance for Global Health

About • Study & Mobility • Research • Campus Life • News • For Employers • Newsletter

Courses & Training Opportunities

- EUGLOH Consortium Partners**
- Université Paris-Saclay (UPSaclay)
 - Lund University (LU)
 - Ludwig-Maximilians-Universität München (LMU)
 - Universidade do Porto (UPorto)
 - University of Szeged (USZ)
 - University of Alcalá (UAH)
 - Universität Hamburg (UHH)
 - University of Novi Sad (UNS)
 - UiT The Arctic University of Norway (UIT)

translation together

www.translationtogether.org

NCATS eatris lifeArc adMare

erc FET PCN-Horizon2020 MARIE CURIE ACTIONS


Horizon 2020 **Horizon Europe**

EIT Health **IMI** **EDCTP**

COST **ECDC** **JPI**


TRANSCAN **EuroNanoMed3**

instruct ERIC **ICPerMed**



Comunidad de Madrid

Ramon y Cajal University Hospital: Governance (1)



Comunidad de Madrid


Ramon y Cajal University Hospital: Governance (2)

Gerencia Asistencial de Atención Primaria

Hospital Universitario Ramón y Cajal

INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IR-CIS

Universidad de Alcalá



INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IR-CIS

SaludMadrid Hospital Universitario Ramón y Cajal

Universidad de Alcalá



Comunidad de Madrid

Summary

HEALTH CARE



Applying innovative solutions in Cancer Prevention, Diagnosis and Treatment.



EDUCATION AND TRAINING



Strong ties with the University



RESEARCH



Outstanding translational and clinical research skills and experience.



GOVERNANCE



Aimed at integrating, coordinating and empowering the 3 components



Comunidad de Madrid



Thanks

**HOSPITAL UNIVERSITARIO CLINICO
SAN CARLOS
(Full Member)**

Madrid – SPAIN

Dr Jorge Bartolomé





Membership Application


Dr. Jorge Bartolomé





A Pillar of Healthcare in Madrid and Spain

The Hospital Clínico San Carlos is located in Madrid, Spain, serving as a central hub for healthcare in the region. Founded in 1787, it operates under the Madrid Health Service (SERMAS), providing comprehensive medical services to the community.





We are tertiary hospital offering comprehensive medical, surgical and central services.

Oncology patients at our hospital receive holistic care, from diagnosis through to end-of-life support, tailored by our multidisciplinary committees for each pathology.

Our dedicated team ensures precise, empathetic management of all care aspects, providing a seamless and supportive treatment experience.

Alignment with ECI objectives

Commitment to Excellence in Cancer Care

- ✓ We uphold the highest standards in cancer treatment, continually aiming to surpass benchmarks for excellence.
- ✓ Our commitment to top-tier oncological care is reinforced through active participation in various quality improvement programs, ensuring we deliver state-of-the-art care to every patient.



ASCO QOPI[®]
Certification Program
Quality Cancer Care: Recognizing Excellence



ESMO
Designated Centres
of Integrated
Oncology and
Palliative Care



Dirección General de Salud Pública
CONSEJERÍA DE SANIDAD
Comunidad de Madrid

Alignment with ECI objectives

Commitment to Global Collaboration

- ✓ Our hospital actively engages in both local and global networks, significantly enhancing our capabilities.
- ✓ This extensive cooperation enhances our expertise and solidifies our reputation as a reference center for sarcoma treatment, improving patient outcomes globally.



Red Oncológica Madrileña

Alignment with ECI objectives

Commitment to Research and Education

- ✓ Our hospital advances medical knowledge by collaborating with academic institutions and industry leaders to develop innovative treatments and technologies.
- ✓ We also prioritize education, providing training and development programs for healthcare professionals.



Get Our Information

Hospital Clínico San Carlos



Calle Profesor Martín Lagos s/n,
28040 Madrid Spain



<https://www.comunidad.madrid/centros/hospital-clinico-san-carlos>
+34 91 330 3000



Membership Application

Thank You For Your Attention



jorge.bartolome@salud.madrid.org,

**GENERAL CANCER HOSPITAL METAXA
(Full Member)**

Piraeus – GREECE

Mrs Dr Eftychia Tsironi
Medical Services Director





SARANTOS EFSTATHOPOULOS

President of the board & CEO

Dr. EFTYCHIA TSIRONI,

MD, PhD Director of
Medical Service Delegate
of CEO

A few words about Metaxa Hospital

A Public Foundation

Founder:

Aggelos Metaxas,
died in 1954

He donated his fortune
for the purposes of the fight
against cancer.

Our mission



Metaxa Hospital is considered according to Law 2889/2001, a **specialized hospital with main purpose the management of oncology patients.**


Therefore, the Hospital is a point of reference for oncology patients not only in Piraeus but in all Attica and the rest of the country.

“Metaxa” Hospital is one of the four pillars, along with “Saint Savvas”, “Saints Anargyroi” and “Theogeneio“, in the public domain, which support the anti-cancer program in Greece.

**Today Metaxa is
a modern hospital,
which offers
specialized services,
maintaining and
enhancing its anti-
cancer character**



Presentation of services provided



357 beds

Emergency department open every 4 days for diagnosed oncology and thoracic surgical cases

Operation of the following **medical departments**:

DEPARTMENTS OF METAXA HOSPITAL

- Pathology-Oncology
- Endocrinology
- Hematology
- Gastroenterology
- Radiotherapy
- Hematopoietic Cell
- Transplantation Unit
- Surgery
- Gynecology
- ENT
- Thoracic surgery Plastic
- Urology
- Breast unit
- ICU
- Nuclear Medicine
- Infections Department



Day Care Unit

Fully dedicated in the administration of chemotherapy to oncology patients

Home care unit

Operating since 1979

Provides nursing and pharmaceutical care at home by experienced nursing staff

Psychosocial Rehabilitation Services-Community Center of Psycho-Oncology-Pain Clinic


Psychological support of patients, their family members and staff.
Cancer pain relief

Social Service-Volunteering

Social support to patients and their caregivers

The "Association of Friends of Patients of the Piraeus Metaxa Hospital" covers the needs of poor patients with cancer

Data from 2023



Total
admissions:
30801

Emergency
department:
4800

Day
clinic:
19915

Home care:
200
visits/month

Surgical
sector
Surgeries:
2347

Surgeries
– one day:
570

Pathology
sector:
7101

Radiotherapy – Radiation:
90/day
(morning-afternoon)

Therapeutic Hemapheresis:
129

TherapeuticPlasmapheresis:
8


Autologous transplants:
20

Collections of progenitor cells for
autologous transplantation:
55



28 CLINICAL RESEARCH TRIALS

Advantages



DA VINCI ROBOTIC SURGERY SYSTEM

- The only Public Hospital that has a Da Vinci robotic system in Greece
METAXA Hospital can become a training center for robotic surgery in the NHS
The 2nd cycle of the training program entitled: “DA VINCI ROBOTIC SYSTEM - SAFE NURSING PATIENT CARE” co-organized by METAXA and the University of West Attica is already taking place

OTHER MODERN DIAGNOSTIC EQUIPMENT:

- PET-CT/MRI/C' Camera/Linear accelerator-radiology/Digital mammography-mammotome



All-day afternoon operation

OUTPATIENT'S CLINIC

RADIOTHERAPY

CHEMOTHERAPY

AFTERNOON SURGERIES



Location – The largest port in the country (medical tourism)

Quality Policy




A Quality Management System, adapted to the requirements of the International Standard ISO 9001:2015, has been studied, applied and installed as a Management tool since 2019, in the following departments:

Blood donation unit
Day care unit
Home care unit
Emergency department
Radiology department
Administrative admission office

Within the first trimester of 2024, Installation ISO 15224:2017 in:

Endoscopy Gastroenterological Clinic
Oncology clinic Megatherapy
Department
Hematology Clinic
Surgical Clinic
Anesthesiology Department


Our prospects



- Continuous modernization of medical equipment
 - Improvement of the building and hotel infrastructure
 - Creation of an integrated computerized system (electronic patient record)
 - Strengthening of existing interdisciplinary departments (Day Care and Home Care Unit, Pain Clinic, etc.)
 - Creation of new Nursing and Palliative Care services (Guest House for terminally ill patients, etc.)
 - Further Development of Home Care Service (ΟΙΚΟΘΕΝ)
-
- Improvement of the terms and conditions of staff's work



Respect
and protection
of patients'
rights



Cooperation
between
Management
and Employees

THANK YOU



UZ GHENT
(Full Member)
Ghent - BELGIUM


Dr Johan De Munter
Nurse Manager Cancer Centre



Introduction University Hospital Ghent & Cancer Center UZ Ghent

OECI2024 ONCOLOGY DAYS

General Assembly




University Hospital Ghent




Demography of UZ Ghent (2023)


- ▶ 2777 Nurses
- ▶ 1472 Physicians
- ▶ 780 Paramedical staff
- ▶ 1081 Administration staff
- ▶ 873 Other staff



69800 day-admissions
38700 multi-day admissions



28600 outpatient emergency admissions
14900 multi-day emergency admissions



16 partner hospitals
44 collaboration agreements with other hospitals

UZ Ghent Cancer Center

Expertise
Building & Dissemination



Research & development



Inclusive & engaged care



Education & Training



Cancer Care Demographics

- ▶ ± 40000 chemotherapy preparations
- ▶ ± 3000 clinical trials chemotherapy preparations
- ▶ 156 stem cell transplantations
- ▶ Radiotherapy service
- ▶ Oncologic (robotic) surgery
- ▶ Psychosocial cancer care services



PAWO

Patient Advisory Board for Scientific Research






CRIG



HIRUZ

The Health, innovation and research institute



JACIE accreditation
for HEMATOPOIETIC
CELLULAR THERAPY



**ESMO DESIGNATED
CENTRES**

of integrated oncology and palliative care services

KANKERCENTRUM

Het UZ Gent is een gespecialiseerd kankercentrum met een jarenlange ervaring. We behandelen zowel **courante kankers** als **complexe of zeldzame tumoren**. Elke patiënt wordt begeleid door een team van artsen, verpleegkundigen, verpleegkundig consulenten en specialisten, diëtisten, psychologen en sociaal werkers.

Dankzij nieuwe wetenschappelijke inzichten heeft het UZ Gent de voorbije tien jaar **grote vooruitgang** geboekt op het vlak van **kankerdiagnostiek en -behandeling**. Kankerpatiënten en hun familieleden kunnen dan ook rekenen op uitstekende zorg, ondersteuning en omkadering op maat.

Maak een afspraak

[AFSPRAAKEGEGEVENS](#)

Algemene informatie

[CONTACTINFORMATIE](#)

KANKERCENTRUM

[ALLES OVER KANKER](#)
[ZORG EN ONDERSTEUNING](#)
[INFOSESSIES EN DOCUMENTATIE](#)
[KANKER EN COVID-19](#)
[KANKERCENTRUM VOOR VERWIJZERS](#)
[ONDERZOEK EN OPLEIDING IN DE ONCOLOGIE](#)
[BESTUUR EN OPDRACHT](#)


Video: wat het Kankercentrum voor u doet

ALLES OVER KANKER




🔍 Typ hier een zoekterm ZOEKEN

- Verzamelingen**
- Volledige inhoud
- ▶ Invullen
 - ▼ **Kankercentrum**
 - ▼ 1. Supportieve zorg in de oncologie
 - ▶ Aanvragen
 - ▶ Katheterzorg
 - ▼ Management toxiciteiten
 - Immunotherapie-gerelateerde nevenwerkingen
 - Pijn
 - ▶ Toxiciteiten cytostatica en targeted agents
 - MOC flows
 - ▶ Oncologische wondzorg
 - Palliatie
 - 2. Oncologisch handboek
 - ▶ 3. Patiënteninformatiefolders
 - 4. Zorgmap voor patiënten

- 401 resultaten
- [.Risiko stratificatie voor contrastnephropathie op radiologie & medische beeldvorming](#)** 📘
Word document
Deze procedure beschrijft de risico stratificatie van contrastnephropathie bij patiënten die een intraveneus contrast onderzoek met joodhoudende contrastmiddelen op radiologie moeten ondergaan
 - [Acute huidreacties \(radiodermitis\) bij patiënten met externe radiotherapie: preventie, behandeling en aanpak van bloeding, jeuk, pijn en infectie](#)** 📘
Interactief document
Deze procedure beschrijft het voorkomen van en de preventie en behandeling van acute huidreacties (radiodermitis) bij patiënten met externe radiotherapie. Daarnaast worden ook het voorkomen en aanpak van daarbijhorende verpleegproblemen bloeding, jeuk, pijn en infectie besproken.
 - [Afschakelen van een Dosi - Fuser pomp](#)** 📘
Standaard verpleegprocedure
Deze verpleegkundige procedure beschrijft het afsluiten van een dosi-fuser ® pomp na beëindigen van de chemokuur.
 - [Algemene huidzorg tijdens doelgerichte kankerbehandeling](#)** 📘
Standaard verpleegprobleem
Deze procedure beschrijft de principes voor een goede huidzorg tijdens een doelgerichte kankerbehandeling ter preventie van mogelijke huidreacties.
 - [Basistekst mondzorg](#)** 📘
Beleid algemeen gebruik
Dit beleidsdocument beschrijft de verschillende aspecten die aan bod komen voor het handhaven van goede mondzorg.
 - [behandeling van anemie bij cytostaticabehandelingen \(cytohandboek - algemeenheden\)](#)** 📘
Word document
 - [Behandeling van thrombopenie bij cytostaticabehandelingen \(cytohandboek - algemeenheden\)](#)** 📘
Word document
 - [Bijwerkingen bij immunotherapie \(irAE's\): colitis en hepatotoxiciteit](#)** 📘
Medisch Protocol

PROJECT U

2023-2029





Education & training



Research & development



Leadership & Network



(E-)Care & Care Coordination



Patient & Public Involvement



PROJECT U

2029

The best way

to improve Quality cancer care

is to improve it together!

The OECI Network

- ★ OECI Member A&D certified Comprehensive Cancer Centre
- ★ OECI Member A&D certified Cancer Centre
- ★ OECI Member A&D certified Cancer Centre
- ★ OECI Member A&D certified Cancer Centre
- ★ OECI Member A&D certified Cancer Centre





Johan De Munter, RN, PgCert

Nurse Manager Cancer Centre UZ Gent
• Johan.demunter@uzgent.be

Past President [European Oncology Nursing Society](#)

Universitair Ziekenhuis Gent

C. Heymanslaan 10 | B 9000 Gent

T +32 (0)9 332 21 11

E info@uzgent.be

www.uzgent.be

Volg ons op



Thank
You




**ODENSE UNIVERSITY HOSPITAL –
SOUTH DENMARK REGION
(Full Member)**

Odense – DENMARK

Stefan Starup Jeppesen (Chief Physician)

Trine Bruus Zachariassen (Chief Nurse)





OUH Odense University Hospital OECI General Assembly in Helsinki

Stefan Starup Jeppesen
Chief Physician, Ass. Professor, PhD

Trine Bruus Zachariassen
Chief nurse, MPG



The Danish Health Sector

Health care is free for all – paid by taxes

5.9 million inhabitants in DK

5 regions: Health care

98 municipalities: Home care

Danish health care in numbers

60 Public hospitals + 10 Private hospitals


2000 GP clinics

1100 Specialists

330 Pharmacies



Region of Southern Denmark



OUH - a university hospital for the region

OUH has a regional responsibility:
Backup og collaboration with other hospitals and health care institutions.

- 296 of 315 regional specialized hospital services
- 432 of 656 highly specialized hospital services
- 18 highly specialized hospital services, with OUH as the only hospital with the service in Denmark



OUH – A main centre in Danish health care

10% of the Danish hospital activity
University hospital with all medical specialities

The patients

752.000 outpatients visits per year
109.000 acute outpatients per year
290.000 telephone- or videoconsultations
85.073 inpatients discharged per year
896 hospital beds

Finances

Budget in 2024: 8,2 million euros



Employees

10.980 employees

OUH – the employees

Employees

10.980 (9.412 full-time)

9.118
in Odense

1.675
in Svendborg

171
in Nyborg and on Ærø

465

employees in administration
and service departments

236

students, employees in
subsidised or flex positions

3.464
nurses

1.951
doctors and dentists

1.589
service and cleaning
assistens

1.136
medical secretaries

684
Biomedical and laboratory
technicians

477
other nursing staff

245
therapists

266
radiographs

218
midwives



Research - generating new and better treatments

Collaboration: Working together across disciplines, sectors, and countries.

Research strategy: Together we create the patient treatment of the future

- Research for and with patients and relatives
- Evidence-based medicine
- Excellent research collaboration
- A strong research culture
- Attractive career paths



OUP research facts:

5 elite research centres
5 centres of excellence
13 front line centres
119 professors
78 adjunct professors
296 PhD students

Moving towards New OUH

New OUH (including psychiatry) will cover approx. 278,000 m²

- 855 beds
- 52 operating theatres
- 379 outpatient clinics

The hospital will be located and built together with the University of Southern Denmark.



Why does OUH seek membership of OECI?

The desire to ensure high standards of cancer care through certification.

To increase collaboration through networking between leading cancer specialists and research institutions.

To further increase participation in international research projects and clinical trials.

To continually strive for more effective and integrated treatment plans for the benefit of patients.




DEPARTAMENTO DE SALUD CLINICO-MALVARROSA (Full Member)

Valencia – SPAIN

Dr. Álvaro Bonet, Managing Director



Structure of Health Department Clínico Malvarrosa – Hospital Clínico Universitario de Valencia




Total population 703.619 habitants

Health Departments	Poblation
Sagunto	161.879
Clínico-Malvarrosa	357.552
Arnau Vilan.-Llíria	338.547
La Fe	297.102
Requena	51.825
General Valencia	376.560
Doctor Peset	283.629
La Ribera	265.099
Gandía	184.188
Xàtiva-Ontinyent	195.675

* Data from Sistema de Información Poblacional SIP (dec. 22)

Structure of Health Department Clínico Malvarrosa – Hospital Clínico Universitario de Valencia



Population

Direct health care to 357.552 hab.
Reference to a further 346.067 hab.

- **Total population 703.619 hab.**
20% are 65y plus


Facilities

- 2 Hospitals (1 general+1 surgical)
- 33 primary care centers


Organization

- Shared Electronic clinical record
- Guidelines and a fast track protocol (when cancer suspicion)

Structure of Health Department Clínico Malvarrosa – Hospital Clínico Universitario de Valencia



Structure of Health Department *Clínico Malvarrosa* – Hospital *Clínico Universitario de Valencia*



GREGORIO MARAÑÓN
GENERAL UNIVERSITY HOSPITAL
(Full Member)

Madrid – SPAIN

Prof. Miguel Martín Jiménez

Head of Medical Oncology Service



Gregorio Marañón General Univesitary Hospital




Prof. Miguel Martín Jiménez
Head of Medical Oncology Service
Gregorio Marañón General University Hospital



Reference Hospital

Quality of Care, Teaching, Research and Humanization





A **University** hospital

Teaching: it is our identity mark

Associated with Madrid Complutense University

Undergraduate: 1.283 students

Postgraduate: 581 resident physicians and
pharmacist in formation

249 university members

6 university full professors





A High complexity hospital

New and innovative facilities

Multidisciplinary teams

Collaboration with national and international onco-hematology groups

Collaboration with patient's associations

YEAR	Nº onco-hematological patients seen in tumor boards per year
2021	5.620
2022	6.012
2023	6.218





A Research Hospital

Gregorio Marañón Research Institute



A Research Hospital



PUBLICATIONS IN LAST 5 YEARS

HEMATOLOGY

YEAR	Q1 number	N publications	IF Total	Median IF	Citations nº
2019	13	38	122,3	3,22	413
2020	32	54	335,4	6,21	1008
2021	35	87	780,9	8,98	932
2022	28	63	362,2	5,75	209
2023	27	54	354,5	6,56	39
TOTAL	135	296	1955,3	6,14	2.601

ONCOLOGY

YEAR	Q1 number	N publications	IF Total	Median IF	Citations nº
2019	35	63	680,1	10,79	5288
2020	37	82	1063,5	12,97	3472
2021	50	87	1086,3	12,49	1732
2022	35	72	678,7	9,43	734
2023	29	68	791,2	11,64	69
TOTAL	186	372	4299,8	11,46	11.295



A Research Hospital

CLINICAL TRIALS


Oncology Clinical Research Unit

Phase I to III Clinical Trials

More than 300 patients enrolled yearly

Colaboration with patient's associations

% PATIENTS INCLUDED IN 2023 IN CLINICAL TRIALS



Number of PHASE I trials

Number of PHASE II-III trials

Year	Number of PHASE I trials	Number of PHASE II-III trials
2023	48	240
2022	48	166
2021	41	198
2020	28	121
2019	51	192

An Oncology Research Hospital


TRASLATIONAL LABORATORY

BIOMARKERS/NGS

PATIENT DERIVED XENOGRAPHS

TUMOR BANK AND COLLECTION

HEREDITARY FAMILIAR CANCER UNIT






An Humaniced Hospital

Comfortable environments

Colaboration with patient's associations

Workshops for patients



**AKERSHUS UNIVERSITY HOSPITAL TRUST
(Full Member)**

Lorenskog – NORWAY

Dr Geir Arne Larsen

Head of Cancer Development Program



Serving
600 000 inhabitants as
primary specialized caregiver

Somatic beds: 837
Psychiatric beds: 295

Number of employees 13 000
Budget 1,2 billion euro

Located in the greater Oslo
area, Norway




Cancer care in brief

- 3500 new cancer patients a year
- 33 Surgical units, including 2 x DaVinci systems
- Medical oncology,
- 5% of new referrals included in clinical studies
- Radiotherapy to be established in 2030
- Precision medicine established



Collaboration with OUS on clinical cancer pathways

- All pathways requiring radiotherapy
- Pancreas, Liver, Gallbladder cancer
- Oesophagus and Proximal stomach cancer
- Gynecological cancer
- Head and neck cancer
- Sarcoma



Human touch and empathy
– with professional skill

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO

(Associate Member – Type A)

Madrid – SPAIN

Fernando Neira, Executive Director






HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA

MEMBERSHIP CANDIDACY TO THE OECI-EEIG

Fernando Neira
Executive Director

FIB Hospital Universitario Puerta de
Hierro-Majadahonda





<http://www.centrossanitarios.saludmadrid.org/Mapas/RedHospitales.as>

px

- Created in 1964, relocated in 2008
- Public Hospital, belonging to SERMAS
- 613 rooms/beds, around 3,000 professionals
- Top 10 by reputation in Spain
- Associated with Universidad Autónoma de Madrid, among the top 200 Universities in the world
- Digital: 1st HIMSS Stage 6 among large hospitals in Madrid
- Serves a population of more than 500.000 people



● Hospitalization

- 529 single rooms

● Day Hospital

- 64 posts

● Dialysis

- 26 posts

● Intensive care

- 52 camas

● ER

- General ER: 22 observation beds
- Pediatric ER 6 observation posts

● Consultations

- 147 consultations
- 48 technical and hospital examination rooms

● Operating rooms

- 22 operating rooms
- 2 operating rooms for experimental surgery

● Delivery Rooms

- 12 dilatation and delivery rooms
- 1 high risk patients delivery room

● Neonatology

- 24 posts
- 6 neonatal intensive care posts



ALL SPECIALITIES



Allergology
Cardiology
Palliative Care
Dermatology
Endocrinology and Nutrition
Gastroenterology
Geriatrics
Hematology and Blood
Transfusion
Intensive Care Medicine
Internal Medicine
Nephrology
Pulmonology
Neurology
Medical Oncology
Radiation Oncology
Psychiatry
Rehabilitation
Rheumatology

Anesthesia and Resuscitation
Cardiac Surgery
Pediatric Surgery
General Surgery and Digestive
System
Maxillofacial Surgery
Plastic and Reconstructive Surgery
Thoracic Surgery
Neurosurgery
Ophthalmology
Otorhinolaryngology
Traumatology and Orthopedic
Surgery
Urology

Obstetrics and Gynecology
Pediatrics

Admission and Clinical Documentation
Patient Care and Social Work
Transplant Coordination
Clinical Pharmacology
Preventive Medicine
Radiotherapy Physics
Occupational Risk Prevention Service

Pathological Anatomy
Clinical Biochemistry
Hospital Pharmacy
Hematology – Blood Bank
Immunology
Nuclear Medicine
Microbiology
Neurophysiology
Radiodiagnosis

Recruitment and contracts
Financial Management
Information Technology
Human Resources

CSUR

- Lung Transplant
- Cardiopulmonary Transplant
- Familial Cardiomyopathies
- Multiple Sclerosis
- Total Body Irradiation for
Mycosis Fungoides

- **Universities and schools where teaching is provided:**

- **Autonomous University of Madrid.**
 - **Bachelor's Degree in Medicine:** 245 students. 74 faculty
 - **Bachelor's Degree in Nursing:** 210 students
- **Francisco de Vitoria University. Bachelor's Degree in Nursing:** 51 students
- **Red Cross. Bachelor's Degree in Nursing:** 59 students
- **Camilo José Cela University. Bachelor's Degree in Nursing:** 105 students
- **Puerta de Hierro Specific Vocational Training Center:** 227 students




11 editions
+200 speakers

300 attendees/year
+3000 attendees in total



EFQM





INSTITUTO DE INVESTIGACIÓN SANITARIA
PUERTA DE HIERRO - SEGOVIA DE ARANA
Hospital Universitario Puerta de Hierro Majadahonda



5 Research Areas

45 Research Groups

412 Researchers

40 PIs

Research Group	PI	Nº Pub.
LUNG CANCER	MARIANO PROVENCIO PULLA	73
HEART FAILURE AND CARDIOMYOPATHIES	PABLO GARCÍA PAVÍA	44
INTERNAL MEDICINE	JUAN ANTONIO VARGAS NÚÑEZ	67
PRIMARY CARE-SPECIALIZED CARE	M ^a ÁNGELES GÓMEZ MATEOS	51
HEMATOLOGY	RAFAEL DUARTE PALOMINO	37
HEPATOLOGY	JOSÉ LUIS CALLEJA PANERO	25
HEART TRANSPLANT	JAVIER SEGOVIA CUBERO	29
CLINICAL PHARMACOLOGY	CRISTINA AVENDAÑO SOLÁ	10
NURSING AND HEALTH CARE	MONTSERRAT SOLÍS MUÑOZ	41
MMUNE BIOMARKERS AND IMMUNOTHERAPIES	JAVIER CARBONE CAMPOVERDE	6

CLINICAL TRIALS / OBSERVATIONAL STUDIES




Active

1.189

(+61)

+ 5,4%



CT OS₂₀₂₂

131

(-21)

-13,8%



CT OS

NEW

yy (xx)

2023 2023 vs

PUBLICATIONS



Nº publications

824

+ 3% (Respecto 2022)



D1 Q1

Impact factor (JCR 2022)

5.053

+ 6 %

Año	Nº Pub. Totales	Q1	Q2	Q3	Q4	Factor Impacto Acc
2010	222	60	57	39	42	677,23
2011	220	82	55	24	27	729,96
2012	263	101	59	28	28	954,58
2013	342	139	83	43	38	1.208,09
2014	320	120	70	44	42	1.112,24
2015	340	142	75	48	43	1.289,12
2016	421	167	97	50	57	1.697,77
2017	491	193	90	74	62	1.916,07
2018	558	184	115	84	82	2.076,49
2019	626	225	126	113	70	2.772,05
2020	667	253	161	109	76	3.483,93
2021	708	290	191	85	64	5.090,10
2022	797	275	270	90	52	4.754,10
2023	824	313	210	96	69	5.052,96


PATENTS




Patents

6

(=)




Utility Models



Licences



CANCER





Dr MARIANO PROVENCIO, Chief Medical Oncology Department HUPHM

- 2011-Present - Full Professor Universidad Autónoma de Madrid
- 2012-Present – Scientific Director, Puerta de Hierro-Segovia Arana Biomedical Research Institute
- 2007-Present – President, Spanish Lymphoma Oncology Group (GOTEL)
- 2014-Present – President, Spanish Lung Cancer Group (SLCG)

Over 339 publications; 68 books/books chapters and 488 papers and invited lectures. He´s been cited over 25,000 times; has an h-index of 69 and an i10-index of 226.
Supervisor of 19 PhD dissertations.



67 STAFF:
15 MEDICAL ONCOLOGIST, 15
RESIDENTS, 2 NURSES, 15
CLINICAL RESEARCH STAFF,
21 RESEARCHERS


CTS in Oncology HUPHM



	Lung	Breast	GI	Linfoma	Sarcoma	Others	TOTALES
2014	49	21	23	3	2	42	140
2015	46	9	36	7	2	23	123
2016	62	17	23	9	3	64	178
2017	104	28	28	3	4	17	184
2018	56	16	25	5	0	15	117
2019	51	7	53	4	0	25	140
2020-2024	545	92	99	4	0	265	1.005


Phase I CLINICAL TRIAL UNIT

- Ph I trials ongoing, >100 patients enrolled
- **First in Human**
- State-of-the-art equipment for patient safety
- Medical Image Workstation



CERTIFICATIONS AND AWARDS


YEAR	AWARDS
2020	<ul style="list-style-type: none"> Best in Class (BIC) in the category of Best Oncology Service in Spain. Entity: URJC Innovation Chair and Gaceta Médica. First Prize Better Research Project 2020 Award for 'Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial' in Lancet Oncol, with an impact factor of 41.316.
2022	<ul style="list-style-type: none"> 2nd prize for the best communication in poster format, EAHP-SH Meeting, Florence 2022. Entity: EAHPSH. Awarded Researcher: Lucia Pedrosa. 1st Prize for the best communication for 'An artificial intelligence-based tool for supporting precision medicine in lung cancer patients: results from the CLARIFY study', XI Educational Symposium of the Spanish Lung Cancer Group. Entity: GECP. 'Excellence and Quality in Oncological Care (ASCO QUOPI Program)' X edition Awards from the ECO Foundation. Entity: Foundation for Excellence and Quality in Oncology. First Prize for Best 2022 Scientific Paper Award for 'Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer' in New Engl J Med, with an impact factor of 176.082. Entity: Puerta de Hierro-Segovia Arana Health Research Institute. First Prize Better Research Project 2022 Award for 'Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage III Non-Small-Cell Lung Cancer (NADIM phase II trial)' in J Clin Oncol, with an impact factor of 50.73. Entity: Puerta de Hierro-Segovia Arana Health Research Institute.
2023	<ul style="list-style-type: none"> Best in Class (BIC) in the category of Best Oncology Service in Spain. Entity: URJC Innovation Chair and Gaceta Médica. Extraordinary Award for the Best Spanish Scientific Publication in Oncology, NADIM II, XI Edition of the ECO Awards. Entity: Foundation for Excellence and Quality in Oncology. III GÉTICA's Research Article Awards for the article 'Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer'. Entity: Spanish Group of Immuno-Biological Therapies in Cancer.



ESMO Designated Centre of Integrated Oncology and Palliative Care

Best in Class (BIC) in the category Best Medical Oncology Service in Spain

American Society Clinical Oncology Certification QOPI 12





ten. **Hospital Universitario**

SaludMadrid **Puerta de Hierro Majadahonda**

ERRE E LENCIA
EUROPEA

500+
EN910bs

FUNDACAO ANTONIO PRUDENTE
(Camargo CC)
(Associate Member – Type B)

San Paulo – BRASIL

Dr Victor Piana de Andrade, Chief Medical Officer





**A.C. Camargo Cancer Center
São Paulo - Brazil**

**Victor Piana de Andrade, M.D, PhD
C.E.O.**



A.C. Camargo Cancer Center



Free-standing Cancer Center since 1953

Private not-for-profit organisation

Qmentum International Accreditation, Diamond level

International Cancer Network – PMH Global Program

First in Brazil

- Surgical Oncology residency - 1953
- Head & Neck surgery - 1953
- Pediatric Oncology - 1964
- Biobank - 1997
- Cancer Genomic Sequencing – 2000
- PET-CT 2001
- Immunotherapy 2012
- Nurse Navigation - 2016
- CAR-T cell - 2023

A.C. Camargo Cancer Center - São Paulo, Brazil

5,000 professionals

650 specialized doctors, 250 residents

13 Disease Centers with MDTs

- * Protocols, Clinical Pathways
- * Nurse Navigation
- * Outcome & Cost measurements
- * Tumor Boards & Research Boards

400 beds; 16% ICU beds

22 Pediatric/AYA Cancer unit

11 BMT / CAR-Tcell unit

27 Operating rooms ; **4500+** robotic surgeries

4 LINACs, brachytherapy, intraoperative radiation

190 consultation offices – 1500 appointments/day



2023:

96,000+ patients

8,000+ new malignant cases

Net Promoter Score: 89

CANCER OBSERVATORY

A.C. CAMARGO
CANCER CENTER
2000 to 2020

Diego Rodrigues Mendonça e Silva
Maria Paula Curado
José Humberto Tavares Guerreiro Fregnani

99.000+ patients fully
treated at
A.C. Camargo

Cancer type (ICD-10) – Males	Five-year global survival rate								Log-rank test p-value
	2000-2004		2005-2009		2010-2014		2015-2017		
	Deaths/total	%	Deaths/total	%	Deaths/total	%	Deaths/total	%	
Squamous cell carcinomas of oropharynx (C01, C02.4, C05.1, C05.2, C09-C10)	75/115	34.8	62/128	51.4	117/233	47.2	44/143	64.0	<0.001
Squamous cell carcinomas of oral cavity (C02-C06, except C05.1 and C05.2)	81/142	43.0	69/136	49.2	82/201	56.2	42/164	70.2	<0.001
Adenocarcinomas of stomach (C16)	101/135	25.2	129/199	35.2	196/323	36.3	81/197	51.0	<0.001
Adenocarcinomas of colon and rectum (C18-C20)	82/206	60.2	152/423	63.9	218/760	68.7	118/560	74.7	0.001
Adenocarcinomas of lungs (C34)	129/144	10.4	96/118	17.9	162/271	34.2	76/187	51.1	<0.001
Melanoma of skin (C43)	31/111	71.9	48/268	82.0	71/503	83.0	23/423	92.9	<0.001
Adenocarcinomas of prostate (C61)	120/728	83.4	146/1519	90.0	230/3151	91.3	87/2084	94.2	<0.001
Renal cell carcinoma (C64)	27/57	52.6	24/98	75.4	55/342	81.4	29/349	89.3	<0.001
Bladder carcinomas (C67)	39/84	53.3	57/118	51.2	64/220	67.8	27/106	68.1	0.002
Papillary thyroid carcinoma (C73)	2/64	96.9	2/118	98.2	9/383	97.3	2/349	99.4	0.306
Hodgkin's lymphoma (C81)	9/63	85.7	8/64	87.5	10/90	88.1	3/54	93.1	0.640






Figure 9. Estimated five-year survival for squamous cell carcinomas of the oropharynx (C01, C02.4, C05.1, C05.2, C09-C10) recorded in the HCR of the ACCCC, 2000-2017.

Type of Cancer	# ACCamargo Patients	5-year Overall Survival		
		A.C.Camargo (%)	SEER (USA) (%)	NordCan (Sweden) Women/Men (%)
Breast Cancer C50	1953	92.6	90.6	92
Prostate Cancer C61				
Melanoma C43	663	91.3	93.7	95.5/93.9
Colorectal Cancer C18	454	71.6	63.9	70.3/67.5
Gastric Cancer C16	210	49.4	33.3	32.2/26.9
Oral Cavity Cancer C02-C06	158	66.7	68	69.8/62.2
Oropharyngeal Cancer C01-C02-C05 -C09-C10	111	59.8	72.8	71.6/68.3
Lung Cancer C34	151	46.5	29.8	29.3/22.4
Cervix Cancer C53	91	76.5	66.7	70.9
Multiple Mieloma C90	22	60.1	57.9	61.6/62.2

ICHOM Incontinence Localized prostate cancer





Education in Oncology for all 27 states in the country

First Oncology Residency in Brazil - 1953

2,000+ residents trained to date

25 specialties: diagnosis, treatment & rehab

2023 Largest Oncology Residency Program:

74 M.D.: Clinical Oncology, hematology, surgery, radiotherapy, pathology, Imaging, nuclear medicine, palliative care


21 specialized nurses, speech and physical therapists, psychologists, physicists, dentists, nutritionists


1000+ Master's and Doctoral degrees since 1997 ; **2023: 41**

LifeLong Learning portfolio



Number of research articles (PubMed) - A.C. Camargo Cancer Center, 1983 - 2023





2023: Top2 recruiter for multiple myeloma CAR-Tcell – CARTITUDE-V - trial

A.C. Camargo Cancer Center

Social Responsibility

- **City of São Paulo**

- Complex Cancer Care; 130,000 patients to date

- **Regional**

- Implementantion Science – screening and treatment
- Care coordination

- **National: 27 states/5276 cities**

- Workforce development; online training

- **International**

- Resident training for all LATAM countries
- Missions to Mozambique, Angola, Uganda
- UICC Master Course – Cancer Center Implementation 2022/23



Why A.C. Camargo Cancer Center & OECI

- **Brazil is going to double its cancer burden in 30 Years**
 - Call to action
 - 210 million inhabitants is a huge opportunity for research
- **OECI can help accelerate:**
 - Implementation Science for prevention
 - Value-driven clinical practices
 - Data Managing and Sharing
 - Research collaborations & Clinical Trials
 - Accelerate innovation, including AI
 - Workforce education
- **ACCamargo can help**
 - OECI World – LATAM & Portuguese speaking countries
 - High volumes of rare cancers in Biobank
 - Clinical and Research expertise



TURKIYE CANCER INSTITUTE

(Associate Member – Type B)

Istanbul – TURKEY

On behalf of the Institute:
Prof. Claudio Lombardo





Trkiye Cancer Institute


Assoc. Prof. Burcu YCEL


Director of Trkiye Cancer Institute


June 2024


Health Institutes of Türkiye (TÜSEB)


➤ 9 research institutes established in line with requirements of health science and technology.


 Related institution of the Ministry of Health


 Strong state support

 Established in 2014

 Main Body of Health R&D in Türkiye

 Connection with all governmental institution & public hospitals

 Experience in Clinical Trials



Campuses of TÜSEB



**Ministry of Health
Ankara, TÜRKİYE**



**Istanbul Kosuyolu Campus
Main Building
İstanbul, TÜRKİYE**

- TÜSEB Administrative Units
- Indigenization Coordination Center
- Clinical Research Coordination Center

Aziz Sancar Research Center Ankara, TÜRKİYE

- Biotechnological Pharmaceuticals and Vaccine R&D and Training Center (BIYASAM)
- Türkiye National Genome Research Laboratory (TUGEM)
- Cancer Research Laboratory
- National Biobank
- COVID-19 Diagnostic Center



Key Performance Indicators

The strategic plan of TÜSEB (2024-2028)

- ❑ The planning and execution of cancer-related activities in this administration's strategic plan.
- ❑ The percentage achievement rates of the targets are reported to the Presidency of Republic of Türkiye and made publicly available on a regular basis every year.
- ❑ To conduct innovative scientific research in the field of cancer and supporting personalized medicine practices.



2024-2028
STRATEJİK PLANI

Mission

To place Türkiye among the leading countries in the prevention, diagnosis and treatment of cancer by developing innovative health strategies.

Vision

To become a leading organization that is innovative and able to offer global solutions to fight cancer.

Objectives of Türkiye Cancer Institute

Fight against cancer!

To develop strategies to beat cancer

To conduct and support R&D activities

To collaborate with national authorities, initiatives and academia

To support the development of National Cancer Plan

To contribute to the development of accreditation guidelines for cancer-related health services



Departments, Advisory Board and Affiliations of Türkiye Cancer Institute

Departments

- Cancer Epidemiology and Preventive Oncology Unit
- Clinical Oncology and Clinical Research Unit
- Basic Oncology, Cancer Genetics and Cancer Molecular Biology R&D Unit
- Tumor Immunology, Cancer Vaccine, Cellular Therapies in Cancer Treatment and Transplantation Unit

Scientific Advisory Board

- Basic Oncology, Cancer Genetics and Cancer Molecular Biology Board
- Clinical Oncology and Research Scientific Advisory Board

Affiliated Centers



İstanbul Göztepe Prof. Dr. Süleyman Yalçın City Hospital



Ankara Bilkent City Hospital

Projects of Türkiye Cancer Institute

- Research activities within the framework of the European Cancer Mission and the European Plan to Beat Cancer
 - Türkiye National Genome and Bioinformatics Project
 - Personal Medicine Approach in Bladder Cancer Therapy: Genomic/Transcriptomic Analyzes and Tumor Modeling Project,
 - ECHoS-Establishing of Cancer Mission Hubs: Networks and Synergies
 - EUonQoL-Quality of Life in Oncology: Measuring What Matters for Cancer Patients and Survivors in Europe
 - Establishing Comprehensive Cancer Research Center (patient-oriented center supporting cancer research through collaborations with government, industry, academia and clinics from different disciplines)





The Türkiye National Genome Center (TUGEM) website and the Türkiye Genome Project Data Sharing Portal Details have been opened for researchers' use!

Congratulations to our country!



Collaborations, Activities & Events

- ❑ We are a member of ICPeMed International Consortium
- ❑ Meetings with National/International consortiums, stakeholders, pharma industry, regulatory agencies.
- ❑ Project calls for Cancer Treatment to national researchers via specific programs
- ❑ Organizing congresses where national and international researchers participate – TÜSEB Future Health Genomics Congress 2023
- ❑ Increasing public awareness through panels and seminars
- ❑ Improving cancer preventing strategies with the Cancer Department of Ministry of Health





Thank you

Contact:

Assoc. Prof. Burcu YÜCEL: burcu.yücel@tuseb.gov.tr

Dr. Serkan YAMAN: serkan.yaman@tuseb.gov.tr

TÜSEB İstanbul Yerleşkesi, Koşuyolu Mahallesi, Koşuyolu Caddesi No: 71 Kadıköy / İstanbul / TÜRKİYE

T +90 216 547 26 00

tke@tuseb.gov.tr

<https://www.tuseb.gov.tr/en>

**SPECIALISED HOSPITAL
CONTROL AGAINST CANCER BLIDA
(Associate Member – Type B)**

Blida – ALGERIA

Prof. Adda Bounedjar





Centre Anti Cancer BLIDA



The Candidacy to the OECI Membership


Prof Adda BOUNEDJAR



Presentation of the Center



- ❑ Blida Cancer Center is a specialized cancer treatment center located in BLIDA, ALGERIA.
- ❑ **academic center** (university hospital center) **University of Blida 1**
- ❑ It is a **referral center** for cancer care in ALGERIA.
- ❑ The center has seven departments: **Medical Oncology, Cancer Surgery, Radiotherapy, Haematology, Central Pharmacy, and a Central Laboratory, nuclear medicine department.**



Cancer Surgery department



- Staff
 - 04 Professors + Assistants Professor + 05 specialists + > 10 doctors
- Senology unit + Gynecology Unit + Unit of Digestive Cancer + Consultation Unit + Emergency unit .
- Referral service for liver surgery, breast surgery and gynecological surgery .
- mdt Cancer digestif (CAC) , RCP Gynécologie , RCP Cancer du sein

مصلىة اللىءاوى بالأشعة
SERVICE RADIOTHERAPIE ONCOLOGIE

المرءوم بروفيسور عباء مسعود

Radiotherapy Department



□ Staff :

- 02 Professeurs + 02 Assistants Professor + 05 specialists + 08 doctors

□ Service doté de 2 simulateurs et 2 accélérateurs

□ Moyen de patients / an



Central laboratory

- Our central laboratory performs a wide range of tests to diagnose and monitor cancer patients.
- The laboratory also provides research support for cancer research projects.



Central pharmacy

- Our central pharmacy provides all of the medications needed to treat cancer patients.
 - Chemotherapy
 - Target therapy
 - Immunotherapy and more
- budget estimated at



Medical Oncology department



- ❑ A department with a great team
 - 05 Professors + 08 Assistants Professor + 16 specialists + 01 haematologist + 01 gastroenterologist + 01 nutritionist doctor + 03 specialist pharmacist + 08 doctors.
- ❑ Hospitalization unit (woman and man) + day hospital unit (Women) senology + day hospital unit (Women) gynecological cancer + day hospital unit (Man) + best supportive care unit + Consultation unit + Emergency unit.

Medical Oncology department



☐ Chairman : Prof Adda BOUNEDJAR

in 2023 = 2200 new patients

in 2024 = so far 1050 new patients until 31 MAY 2024

☐ MDT Digestive cancer Senology , Gynecology , melanoma , neurology , ORL
, Sarcoma and TNE

CLINICAL RESEARCH



- Cancer research laboratory (BLIDA 1 University):
 - Since 2011
 - Attached to BLIDA 1 University
 - 06 Unities
 - Research team
 - Professors / Doctors
 - Medical Coordinator
 - CRA
 - IRC coordinator / IRC
 - Participation in 20 clinical studies phase II , III , and phase IV

CLINICAL TRIALS



BLIDA 1 UNIVERSITY



☐ Now we have 08 ongoing clinical trials

⇒ ICRG study « 0103 »

- Multicentric Proof of concept study infrared laser spectroscopy of liquid biopsies for cancer detection << team Prof J-M Nabholz (France - KSA / Prof Ferenc KRAUSZ Germany Nobel prize....)



⇒ 02 interventional studies Phase 2 :

- ICRG study « 0201 »
- SAFRO study « ALGCAV »



⇒ 01 interventional study Phase 3

- BIOCAD Study « BCD-178 »




⇒ 02 studies about epidemiologic profile (multicentric observational study)

- Epidemiologic profile of Breast Cancer (ROCHE)
- Epidemiologic profile of Lung Cancer (ASTRA ZENECA)




⇒ 02 studies about RWD Phase 4

- RWD TNT Study » (jules bordet)
- RWD trastuzumab biosimilar study (SAIDAL)





PARTNERS



Philippe Aftimos, MD
Institut Jules Bordet – Brussels – Belgium
✉ philippe.aftimos@ch




ELENA GARRALDA, MD, MSc
Vall Hebron Institute of Oncology (VHIO)
✉ egarralda@vhio.i



Jean-Pascal Machiels, MD, PhD
Cliniques universitaires Saint-Luc – Brussels – Belgium
✉ jean-pascal.machiels@ch



Florian Clatot, MD, PhD
Henri Becquerel Centre – Rouen – France
✉ florian.clatot@ch



Caroline Duhem, MD
Centre Hospitalier de Luxembourg
✉ Duhem.Caroline@ch



Jon Amund Kyte, MD, PhD
Oslo University Hospital
✉ jonky@ous-hf.no



Lore Decoster, MD



Jean-Luc Canon, MD



Philippe Barthélémy,




Luis Castelo-Branco, MD



Bassam Janji, PhD, HDR



Adda Bounedjar, MD, PhD
CHU Blida – Blida – Algeria
✉ abounedjar@lih



King Hussein Cancer Foundation
King Hussein Cancer Center

Cancérologie : cibles et traitements ciblés

JCO® Global Oncology
An American Society of Clinical Oncology Journal

Journal of Thoracic Disease

[JCO Glob Oncol](#). 2023; 9: e2300159.

PMCID: PMC10645406

Published online 2023 Nov 9. doi: [10.1200/GO.23.00159](https://doi.org/10.1200/GO.23.00159)

PMID: [37944087](https://pubmed.ncbi.nlm.nih.gov/37944087/)

Africa Guidelines for Hepatocellular Carcinoma Buildup Process

[Ghassan K. Abou-Alfa](#), MD, MBA,^{1, 2, 3} [Mary Afihene](#), MD,⁴ [Marinela Capanu](#), PhD,^{1, 2} [Yuelin Li](#), PhD,^{1, 2} [Joanne F. Chou](#), MPH,¹ [Akwi Asombang](#), MD,⁵ [Olusegun Isaac Alatise](#), MD,⁶ [Adda Bounedjar](#), MD,⁷ [Lina Cunha](#), MD,⁸ [Hailemichael Desalegn Mekonnen](#), MD,⁹ [Papa Saloum Diop](#), MD,¹⁰ [Reda Elwakil](#), MD,¹¹ [Mahamat Moussa Ali](#), MD,¹² [Ntokozo Ndlovu](#), MD,¹³ [Jerry Ndumbalo](#), MD,¹⁴ [Precious Takondwa Makondi](#), MBBBS, PhD,¹⁵ [Christian Tzeuton](#), MD,¹⁶ [Tiago Biachi de Castria](#), MD,^{1, 17} [Adwoa Afrakoma Agyei-Nkansah](#), MD,¹⁸ [Fiyinfolu Balogun](#), MD,^{1, 2} [Alain Bougouma](#), MD,¹⁹ [Blaise Irénée Atipo Ibara](#), MD,²⁰ [Eduard Jonas](#), MD,²¹ [Stephen Kimani](#), MD,²² [Peter Kingham](#), MD,^{1, 2} [Reshad Kurrimbukus](#), MD,²³ [Nazik Hammad](#), MD,²⁴ [Mona Fouad](#), MD,²⁵ [Noha El Baghdady](#), MD,²⁶ [Eloumou Bagnaka Servais Albert Fiacre](#), MD,²⁷ [Vikash Sewram](#), MD,²⁸ [C. Wendy Spearman](#), MD,²¹ [Ju Dong Yang](#), MD,²⁹ [Lewis R. Roberts](#), MD,³⁰ and [Ashraf O. Abdelaziz](#), MD³¹

▶ Author information ▶ Article notes ▶ Copyright and License information ▶ [PMC Disclaimer](#)

This article has been corrected. See [JCO Glob Oncol](#). 2023; 9: e2300440.

Abstract

Go to: ▶

PURPOSE

Hepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like in sub-Saharan Africa. This is affected by the low gross domestic product and human development index, absence of coherent guidelines, and other factors.

⁹Hematology Oncology Service, NMC Royal Hospital Sharjah, Sharjah University, Sharjah, U.

[J Thorac Dis](#). 2019 Dec; 11(12): 5162–5168.

PMCID: PMC69

doi: [10.21037/jtd.2019.12.03](https://doi.org/10.21037/jtd.2019.12.03)

PMID: [320](https://pubmed.ncbi.nlm.nih.gov/320)

Patterns of diagnostic procedures for lung cancer pathology in the Middle East and North Africa

[Abdul Rahman Jazieh](#),^{1, 3} [Adda Bounedjar](#),⁴ [Foad Al Dayel](#),⁵ [Shamayel Fahem](#),⁵ [Arafat Tfayli](#),⁶ [Kakil Rasul](#),⁷ [Hassan Jaafar](#),⁸ [Mohammad Jaloudi](#),⁹ [Turki Al Fayea](#),⁹ [Hatim Q. Almaghrabi](#),⁹ [Hanaa Bamefleh](#),^{1, 2, 10} [Khaled AlKattan](#),^{5, 11} [Blaha Larbaoui](#),¹² [Taha Filalli](#),¹³ [Mufid Al Mistiri](#),⁷ and [Hamed Alhusaini](#)⁵

▶ Author information ▶ Article notes ▶ Copyright and License information ▶ [PMC Disclaimer](#)

Abstract

Background

Accurate pathological diagnosis is the first critical step in the management of lung cancer. This step is important to determine the histological subtype of the cancer and to identify any actionable targets. Our study aimed at evaluating the patterns of procedures used to obtain pathological diagnosis of lung cancer in the Middle East and North Africa (MENA) Region.

PUBLICATIONS

SAFIA STUDY

Randomized Controlled Trial | J Cancer Res Clin Oncol. 2023 Aug;149(9):6171-6179.

doi: 10.1007/s00432-023-04588-3. Epub 2023 Jan 21.

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

K Alsaleh¹, H Al Zahwahy², **A Bounedjar³**, M Oukkal⁴, A Saadeddine⁵, H Mahfouf⁶, K Bouzid⁷, A Bensalem⁸, T Filali⁹, H Abdel-Razeq¹⁰, B Larbaoui¹¹, A Kandil¹², O Abulkhair¹³, M Al Foheidi¹⁴, M Ghosn¹⁵, H Rasool¹⁶, H Boussen¹⁷, A Mezlini¹⁸, A Haddaoui¹⁸, J Ayari¹⁹, M Al Ghamdi²⁰, H Errihani²¹, N Abdel-Aziz²², M Arafah²³, F Dabouz²⁴, M Bahadoor²⁴, S Kullab²⁰, J M Nabholtz²⁰,

King Saud University, Riyadh, Kingdom of Saudi Arabia, and the International Cancer Research Group (ICRG), Sharjah, Unites Arab Emirates

Affiliations + expand

PMID: 36680581 PMCID: PMC9864499 DOI: 10.1007/s00432-023-04588-3

Abstract

Background: The most prevalent subtype of breast cancer (BC) is luminal hormonal-positive breast cancer. The neoadjuvant chemotherapy regimens have side effects, emphasizing the need to identify new strategies.

Objective: Analyze the complete pathologic response (pCR) rate and overall response in a low-risk hormone-positive subset of patients receiving neoadjuvant hormone treatment (NAHT) with or without Palbociclib (a CDK4/CDK6 inhibitor) to boost NAHT effectiveness.

Materials and methods: Based on the upfront 21-gene Oncotype DX or low-risk Breast

LUNG CANCER

ASCO Publications PUBLICATIONS TOPICS SUBSCRIBE AUTHORS ABOUT CAREERS

JCO® Global Oncology
An American Society of Clinical Oncology Journal

OPEN ACCESS | SPECIAL ARTICLES | August 04, 2020



Expression of Immune Response Markers in Arab Patients With Lung Cancer

Authors: Abdul Rahman Jazieh, MD, MPH¹, **Adda Bounedjar, MD**², Sanaa Bamefleh, MBChB, Turki Alfayea, MBBS, Hatim Q. Almaghraby, MBChB, Ayed Belarabi, MD, Wahiba Ouahione, MD, Zoubir Derbouz, MD, Mohammad Alkaiyat, BSN, Khaled Alkattan, MD, Moussab Damlaj, MD, and Walid E. Khalbuss, MD, PhD | [AUTHORS INFO & AFFILIATIONS](#)

Publication: JCO Global Oncology • Volume 6 • <https://doi.org/10.1200/GO.20.00107>

1 593



Abstract

Purpose

Programmed death-ligand 1 (PD-L1) is a marker for checkpoint inhibitor use in the management of solid tumors, especially in non-small-cell lung cancer (NSCLC). Our study was aimed at determining the patterns of PD-L1 expression and cluster of differentiation 8

COVID

Research Article

For reprint orders, please contact: reprints@futuremedicine.com

Predictors of poor precautionary practices towards COVID-19 among cancer patients

Abdul R Jazieh*¹, Assia A Bensalem², **Adda Bounedjar³**, Zineb Benbrahim⁴, Mohamed O Alorabi⁵, Atial M Abusanad⁶, Emad Al-Tashtarkar⁷, Wadiah AMA Alnassar⁸, Abdul RAD El Kinge⁹, Sana Al-Sukhun¹⁰, Abdullah Alsharm¹¹, Hassan Errihani¹², Nafisa A Abdelhafiez¹³, Mohammad Alkaiyat¹⁴ & Hoda Jradi¹⁵

¹Cincinnati Cancer Advisors, Cincinnati, OH, USA

²Medical Oncology Department, Établissement Hospitalier DIDOUCHE Mourad, Faculté de médecine, Université de Constantine 3, Constantine, Algeria

³Université Blida 1 Laboratoire de cancérologie, Faculté de Médecine, BP 270, Route de soumaa, Blida, Algeria

⁴Medical Oncology, Faculty of Medicine of Pharmacy Sciences, University of Mohammed el-Bachir el-Deledji, Morocco

⁵Ain Shams Faculty of Medicine, Clinical Oncology Department, Cairo, Egypt

⁶Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia


⁷College of Medicine, Umm Alqura University, Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia

⁸Kuwait Cancer Control Cancer, Kuwait City, Kuwait

⁹Hematology Oncology Service, NMC Royal Hospital Sharjah, Sharjah University, Sharjah, UAE

¹⁰Hematology/Medical Oncology, Al-Hyatt Oncology Practice, Amman, Jordan

¹¹Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia



PERSPECTIVES

OECI Memberships



more than 04 clinical trials are planned in 2025

CLINICAL STUDY



More Partners



CENTRE DE LUTTE CONTRE LE CANCER
LEON BERARD

ck.com - 2321792921



NATIONAL CANCER INSTITUTE OF UKRAINE
(Associate Member – Type B)

Kiev – UKRAINE

On behalf of the Institute: Thierry Philip



National Cancer Institute in 2021

- 17 scientific departments and labs
- 33 clinical department
- 600 beds inpatients clinic





Olena Yefimenko,
MED.SC.D
CEO

Expertise in:

- Healthcare management
- Healthcare policy



Yurii Kondratskyi,
PhD
Chief of Surgical Oncology

Expertise in:


- Healthcare management
- Clinical & surgical oncology


Our team


- 17 scientific divisions and labs
- 33 clinical department
- 600 beds inpatients clinic
- >1400 employee

Annual activities

10 000 patients - surgical procedures annually
20 000 patients - inpatient clinic including 950 children
110 000 patients - outpatient clinic









NATIONAL CANCER INSTITUTE
Ukraine, Kyiv



Total number of surgeries:

> 10000

per year

Health Care Infrastructure was robbed and destroyed

